Selective embolization with N-butyl cyanoacrylate for metastatic bone disease

Giuseppe Rossi, Andreas F. Mavrogenis, Eugenio Rimondi, Lucia Braccaioli, Teresa Calabrò, Pietro Ruggieri

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the clinical and imaging effect of selective embolization using N-butyl cyanoacrylate (NBCA) as palliation for bone metastases. Materials and Methods: The procedures and effect of 309 embolizations performed in 243 patients were retrospectively analyzed; 56 patients had repeat embolization at the same location at 1-3 months; 197 patients had embolization for progressive bone metastases after radiation therapy. The mean tumor diameter before embolization was 7.8 cm (range 5-30 cm). In all patients, embolizations were performed under local anesthesia through transfemoral catheterization using NBCA in 33% ethiodized oil. The technical success of embolization was evaluated by angiography after completion of the procedure. The clinical and imaging effect was evaluated at follow-up examinations with a pain score scale and use of analgesics, hypoattenuating areas, tumor size, and ossification. Results: In all 309 embolizations, postprocedural angiography showed complete occlusion of metastatic blood supply and greater than 80% devascularization of the lesions. Greater than 50% reduction of pain score and analgesic doses was achieved in 97% of procedures. The mean duration of pain relief was 8.1 months (range 1-12 months). The mean maximal tumor diameter after embolization was 5.5 cm (range 2-20 cm). Variable ossification appeared in 65 patients. Postembolization syndrome, ischemic pain at the site of embolization, paresthesias, skin breakdown, and subcutaneous necrosis were observed in 87 patients. Conclusions: Selective embolization with NBCA is a safe and effective palliative treatment for metastatic bone lesions of various primary cancers; pain relief is temporary.

Original languageEnglish
Pages (from-to)462-470
Number of pages9
JournalJournal of Vascular and Interventional Radiology
Volume22
Issue number4
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Enbucrilate
Bone Diseases
Pain
Osteogenesis
Bone and Bones
Analgesics
Neoplasms
Angiography
Neoplasm Metastasis
Ethiodized Oil
Paresthesia
Local Anesthesia
Palliative Care
Catheterization
Necrosis
Radiotherapy
Skin

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Selective embolization with N-butyl cyanoacrylate for metastatic bone disease. / Rossi, Giuseppe; Mavrogenis, Andreas F.; Rimondi, Eugenio; Braccaioli, Lucia; Calabrò, Teresa; Ruggieri, Pietro.

In: Journal of Vascular and Interventional Radiology, Vol. 22, No. 4, 04.2011, p. 462-470.

Research output: Contribution to journalArticle

Rossi, Giuseppe ; Mavrogenis, Andreas F. ; Rimondi, Eugenio ; Braccaioli, Lucia ; Calabrò, Teresa ; Ruggieri, Pietro. / Selective embolization with N-butyl cyanoacrylate for metastatic bone disease. In: Journal of Vascular and Interventional Radiology. 2011 ; Vol. 22, No. 4. pp. 462-470.
@article{3837d810d2624cd6ae59688874ecbee8,
title = "Selective embolization with N-butyl cyanoacrylate for metastatic bone disease",
abstract = "Purpose: To evaluate the clinical and imaging effect of selective embolization using N-butyl cyanoacrylate (NBCA) as palliation for bone metastases. Materials and Methods: The procedures and effect of 309 embolizations performed in 243 patients were retrospectively analyzed; 56 patients had repeat embolization at the same location at 1-3 months; 197 patients had embolization for progressive bone metastases after radiation therapy. The mean tumor diameter before embolization was 7.8 cm (range 5-30 cm). In all patients, embolizations were performed under local anesthesia through transfemoral catheterization using NBCA in 33{\%} ethiodized oil. The technical success of embolization was evaluated by angiography after completion of the procedure. The clinical and imaging effect was evaluated at follow-up examinations with a pain score scale and use of analgesics, hypoattenuating areas, tumor size, and ossification. Results: In all 309 embolizations, postprocedural angiography showed complete occlusion of metastatic blood supply and greater than 80{\%} devascularization of the lesions. Greater than 50{\%} reduction of pain score and analgesic doses was achieved in 97{\%} of procedures. The mean duration of pain relief was 8.1 months (range 1-12 months). The mean maximal tumor diameter after embolization was 5.5 cm (range 2-20 cm). Variable ossification appeared in 65 patients. Postembolization syndrome, ischemic pain at the site of embolization, paresthesias, skin breakdown, and subcutaneous necrosis were observed in 87 patients. Conclusions: Selective embolization with NBCA is a safe and effective palliative treatment for metastatic bone lesions of various primary cancers; pain relief is temporary.",
author = "Giuseppe Rossi and Mavrogenis, {Andreas F.} and Eugenio Rimondi and Lucia Braccaioli and Teresa Calabr{\`o} and Pietro Ruggieri",
year = "2011",
month = "4",
doi = "10.1016/j.jvir.2010.12.023",
language = "English",
volume = "22",
pages = "462--470",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Selective embolization with N-butyl cyanoacrylate for metastatic bone disease

AU - Rossi, Giuseppe

AU - Mavrogenis, Andreas F.

AU - Rimondi, Eugenio

AU - Braccaioli, Lucia

AU - Calabrò, Teresa

AU - Ruggieri, Pietro

PY - 2011/4

Y1 - 2011/4

N2 - Purpose: To evaluate the clinical and imaging effect of selective embolization using N-butyl cyanoacrylate (NBCA) as palliation for bone metastases. Materials and Methods: The procedures and effect of 309 embolizations performed in 243 patients were retrospectively analyzed; 56 patients had repeat embolization at the same location at 1-3 months; 197 patients had embolization for progressive bone metastases after radiation therapy. The mean tumor diameter before embolization was 7.8 cm (range 5-30 cm). In all patients, embolizations were performed under local anesthesia through transfemoral catheterization using NBCA in 33% ethiodized oil. The technical success of embolization was evaluated by angiography after completion of the procedure. The clinical and imaging effect was evaluated at follow-up examinations with a pain score scale and use of analgesics, hypoattenuating areas, tumor size, and ossification. Results: In all 309 embolizations, postprocedural angiography showed complete occlusion of metastatic blood supply and greater than 80% devascularization of the lesions. Greater than 50% reduction of pain score and analgesic doses was achieved in 97% of procedures. The mean duration of pain relief was 8.1 months (range 1-12 months). The mean maximal tumor diameter after embolization was 5.5 cm (range 2-20 cm). Variable ossification appeared in 65 patients. Postembolization syndrome, ischemic pain at the site of embolization, paresthesias, skin breakdown, and subcutaneous necrosis were observed in 87 patients. Conclusions: Selective embolization with NBCA is a safe and effective palliative treatment for metastatic bone lesions of various primary cancers; pain relief is temporary.

AB - Purpose: To evaluate the clinical and imaging effect of selective embolization using N-butyl cyanoacrylate (NBCA) as palliation for bone metastases. Materials and Methods: The procedures and effect of 309 embolizations performed in 243 patients were retrospectively analyzed; 56 patients had repeat embolization at the same location at 1-3 months; 197 patients had embolization for progressive bone metastases after radiation therapy. The mean tumor diameter before embolization was 7.8 cm (range 5-30 cm). In all patients, embolizations were performed under local anesthesia through transfemoral catheterization using NBCA in 33% ethiodized oil. The technical success of embolization was evaluated by angiography after completion of the procedure. The clinical and imaging effect was evaluated at follow-up examinations with a pain score scale and use of analgesics, hypoattenuating areas, tumor size, and ossification. Results: In all 309 embolizations, postprocedural angiography showed complete occlusion of metastatic blood supply and greater than 80% devascularization of the lesions. Greater than 50% reduction of pain score and analgesic doses was achieved in 97% of procedures. The mean duration of pain relief was 8.1 months (range 1-12 months). The mean maximal tumor diameter after embolization was 5.5 cm (range 2-20 cm). Variable ossification appeared in 65 patients. Postembolization syndrome, ischemic pain at the site of embolization, paresthesias, skin breakdown, and subcutaneous necrosis were observed in 87 patients. Conclusions: Selective embolization with NBCA is a safe and effective palliative treatment for metastatic bone lesions of various primary cancers; pain relief is temporary.

UR - http://www.scopus.com/inward/record.url?scp=79953784184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953784184&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2010.12.023

DO - 10.1016/j.jvir.2010.12.023

M3 - Article

C2 - 21367617

AN - SCOPUS:79953784184

VL - 22

SP - 462

EP - 470

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 4

ER -